127003-40-1

Usage

Uses

Used in Pharmaceutical Industry:
1-(2-(3-methoxyphenyl)ethyl)phenoxy-3-(dimethylamino)-2-propanol is used as a pharmaceutical drug for its potential therapeutic effects on certain medical conditions. 1-(2-(3-methoxyphenyl)ethyl)phenoxy-3-(dimethylamino)-2-propanol's specific application and efficacy would depend on further research and testing to determine its exact properties and how it interacts with biological systems.
Used in Drug Development:
In the field of drug development, 1-(2-(3-methoxyphenyl)ethyl)phenoxy-3-(dimethylamino)-2-propanol may serve as a lead compound for the creation of new medications. Its unique structure could be optimized and modified to target specific diseases or conditions, potentially leading to the development of novel therapeutic agents.
Used in Chemical Research:
As a complex organic compound, 1-(2-(3-methoxyphenyl)ethyl)phenoxy-3-(dimethylamino)-2-propanol can also be utilized in chemical research to study its reactivity, stability, and interactions with other molecules. This information could be valuable for understanding its potential applications and for designing new compounds with similar or improved properties.

InChI:InChI=1/C20H27NO3/c1-21(2)14-18(22)15-24-20-10-5-4-8-17(20)12-11-16-7-6-9-19(13-16)23-3/h4-10,13,18,22H,11-12,14-15H2,1-3H3

Upstream product

• 135159-51-2 sarpogrelate hydrochloride 
• 167145-13-3 2-[2-(3-methoxyphenyl)ethyl]phenol 
• 506-59-2 N,N-dimethylammonium chloride 
• 143212-74-2 1-(2-hydroxyphenyl)-2-(3-methoxyphenyl)ethylene 
• 124-40-3 dimethyl amine 
• 90-02-8 salicylaldehyde 
• 33223-21-1 C₂₆H₂₄ClOP 

Downstream Products

• 1588890-73-6 C₂₆H₃₅NO₉ 
• 1588890-75-8 C₂₆H₃₅NO₉ 
• 135159-51-2 sarpogrelate hydrochloride 

Relevant academic research and scientific papers

Synthesis method of 2-(dimethylamino)-3-(2-(3-methoxyphenethyl)phenoxy)propyl-1-ol

The invention discloses a synthesis method of 2-(dimethylamino)-3-(2-(3-methoxyphenethyl)phenoxy) propyl-1-ol, and belongs to the field of organic chemical synthesis. According to the synthesis method, 2-((2-(3-methoxyphenethyl)phenoxy)methyl)ethylene oxi

Synthesis method for sarpogrelate hydrochloride

The invention discloses a synthesis method for sarpogrelate hydrochloride, and relates to the technical field of medicine organic synthesis. Methoxyl diethyl phosphite 6 and 2-(3-dimethylamino-2-hydroxy)propoxybenzaldehyde 7 are adopted as raw materials,

Process for preparing sand Greythe ester is new hydrochloric acid

The present invention discloses a preparation method of sarpogrelate hydrochloride. According to the preparation method, 2-[2-(3-methoxyphenyl)ethyl]phenol is adopted as a starting reactant, benzyl triethylammonium chloride is adopted as a phase transfer catalyst, the starting reactant, the phase transfer catalyst and epichlorohydrin form an ether in toluene and water, dimethylamine is adopted to carry out aminolysis in a pressurization reactor after the ether is formed to obtain 1-dimethylamino-3-[2-[2-(3-methoxyphenyl)ethyl]phenoxy]-2-propanol, the 1-dimethylamino-3-[2-[2-(3-methoxyphenyl)ethyl]phenoxy]-2-propanol and succinic anhydride are subjected to esterification in acetone, hydrogen chloride gas is directly introduced without recovery and replacement of the solvent to form a hydrochloride, and re-crystallization with acetone is performed to obtain the sarpogrelate hydrochloride refined product, wherein the purity is more than 99%.

Glucuronidation of a sarpogrelate active metabolite is mediated by udp-glucuronosyltransferases 1a4, 1a9, and 2b4

Sarpogrelate is a selective serotonin 5-HT2A-receptor antagonist used to treat patients with peripheral arterial disease. This drug is rapidly hydrolyzed to its main metabolite (R,S)-1-[2-[2-(3-methoxyphenyl)ethyl]phenoxy]-3- (dimethylamino)-2-propanol (M-1), which is mainly excreted as a glucuronide conjugate. Sarpogrelate was also directly glucuronidated to an O-Acyl glucuronide and a Nglucuronide by UDP-glucuronosyltransferases (UGTs) in human liver microsomes (HLMs). Since M-1 is pharmacologically more active than sarpogrelate, we examined glucuronidation of this metabolite in HLMs and characterized the UGTs responsible for M-1 glucuronidation. Diastereomers of O-glucuronide (SMG1 and SMG3) and a N-glucuronide (SMG2) were identified by incubation of M-1 with HLMs in the presence of uridine 59-diphosphoglucuronic acid (UDPGA), and their structures were confirmed by nuclear magnetic resonance and mass spectrometry analyses. Two O-glucuronides were identified as chiral isomers: SMG1 as R-isomer and SMG3 as S-isomer. Using recombinant UGT enzymes, we determined that SMG1 and SMG3 were predominantly catalyzed by UGT1A9 and UGT2B4, respectively, whereas SMG2 was generated by UGT1A4. In addition, significant correlations were noted between the SMG1 formation rate and propofol glucuronidation (a marker reaction of UGT1A9; r = 0.6269, P a marker reaction of UGT1A4; r = 0.6623, P a panel of HLMs. Inhibition of SMG1, SMG2, and SMG3 formation by niflumic acid, hecogenin, and fluconazole further substantiated the involvement of UGT1A9, UGT1A4, and UGT2B4, respectively. These findings collectively indicate that UGT1A4, UGT1A9, and UGT2B4 are the major UGT isoforms responsible for glucuronidation of M-1, an active metabolite of sarpogrelate. Copyright

Development of sarpogrelate external preparation for intractable pain control. I. Pre-formulation study on application of modified β-cyclodextrins

To optimize the formulation of in-hospital sarpogrelate (SPG) preparation for external use, various cyclodextrins (CDs) were investigated for their ability to improve the aqueous solubility and chemical stability of SPG. Although hydrolysis of SPG was mar

Syntheses and Platelet Aggregation Inhibitory and Antithrombotic Properties of ethyl>benzenes

A series of ethyl>benzene derivatives were synthesized and evaluated for their ability to inhibit collagen-induced platelet aggregation in vitro and to protect experimantal thrombosis in mice.The results showed that the compounds were in vitro inhibitors of collagen-induced platelet aggregation.Most of them were also effective in the mouse antithrombotic assay.The compounds were found to be potent antagonists to S2 serotonergic receptor, and good correlation (r = 0.85) between their S2 serotonergic receptor antagonism and their potency as platelet antiaggregatory drugs was observed.Among the compounds studied, monophenoxy>methyl>ethyl>succinate hydrochloride (12b, MCI-9042) was selected for further pharmacological and toxicological evaluation.